简介：高危人乳头瘤病毒 (HPV) 是宫颈癌的病原体，宫颈癌仍然是全球女性癌症死亡的第四大原因。 K14-HPV16转基因小鼠是HPV诱导的癌症的模型，其皮肤经历多步鳞状癌发生，其在组织学和分子上与人类子宫颈的癌发生相似。之前使用 K14-HPV16 小鼠进行的差异调节 microRNA (miR) 筛选显示，miR-21、miR-155、miR-150、miR-146a、miR-125b 和 miR-223 在致癌过程中发挥作用。方法：我们现在的目标是将这些观察结果转化为临床环境，利用癌症基因组图谱 (TCGA) 提供的数据来探索这些 microRNA 是否可以影响宫颈癌患者的生存。结果：结果显示，原发性肿瘤中 miR-150、miR-155 和 miR-146a 表达水平低与总体生存率较差相关。然而，只有 miR-150 和 miR-155 被发现是独立的预测因子，增加了死亡风险。当患者按临床分期分层时，低 miR-150、miR-155、miR-146a 和 miR-125b 与临床 I 期的较差生存相关

Introduction: High-risk human papillomavirus (HPV) is the etiological agent of cervical cancer, which remains the fourth leading cause of cancer death in women worldwide. K14-HPV16 transgenic mice are a model for HPV-induced cancers, which undergo multistep squamous carcinogenesis at the skin, that is histologically and molecularly similar to carcinogenesis of the human cervix. Previous screens of differentially regulated microRNAs (miRs) using K14-HPV16 mice showed a role for miR-21, miR-155, miR-150, miR-146a, miR-125b and miR-223 during carcinogenesis. Methods: We now aim to translate these observations into the clinical setting, using data provided by The Cancer Genome Atlas (TCGA) to explore whether those microRNAs can influence the survival of cervical cancer patients. Results: Results showed that low miR-150, miR-155 and miR-146a expression levels in primary tumors were associated with poor overall survival. However, only miR-150 and miR-155 were found to be independent predictors, increasing the risk of death. When patients were stratified by clinical stage, low miR-150, miR-155, miR-146a and miR-125b were associated with poor survival for clinical stages I&II. Only low miR-150 expression increased the death risk. Conclusion: We conclude that miR-150 and miR-155 may be potentially applied as prognostic biomarkers in cervical cancer patients. However, further investigation is required to determine their applicability.